Table 1.
Immunohistochemistry and relationship with patient and tumour factors.
| Characteristic | Total | p16 (n = 45) | p53 (n = 36) | Other (n = 67) | P |
|---|---|---|---|---|---|
| Site | LP: 25 % (37) WM: 75 % (111) |
LP: 7 % (3) WM: 93 % (42) |
LP: 14 % (5) WM: 86 % (31) |
LP: 43 % (29) WM: 57 % (38) |
<0.01 |
| Age (years) (IQR) | 69 (55–78) |
62 (50–71) |
71 (63–83) |
70 (58–81) |
<0.01 |
| BMI (kg/m2) (IQR) | 29 (24–37) |
30 (23–37) |
31 (24–38) |
28 (24–35) |
0.63 |
| Index of Relative Socio-economic Disadvantage (IQR) | 2 (1–4) |
3 (2–4) |
2 (2–4) |
2 (1–4) |
0.51 |
| Charlson Comorbidity Index (IQR) | 5 (4–8) | 4 (3–6) |
6 (4–8) |
6 (5–8) |
0.02 |
| Smoker | 25 % (34) | 29 % (12) | 9 % (3) | 32 % (19) | 0.03 |
| Australian Born | 76 % (111) | 84 % (38) | 69 % (25) | 73 % (48) | 0.23 |
| Lymphovascular Invasion | 28 % (37) | 14 % (6) | 29 % (10) | 40 % (21) | 0.02 |
| Perineural Invasion | 14 % (18) | 0 % (0) | 24 % (8) | 20 % (10) | <0.01 |
| Largest Diameter (mm) (IQR) | 30 (13–45) |
22 (6–35) |
31 (13–40) |
35 (20–50) |
0.01 |
| Depth of Stromal Invasion (mm) (IQR) | 4.0 (2.0–7.8) |
2.1 (0.6–5.8) |
4.8 (3.4–7.5) |
5.0 (2.1–9.5) |
0.01 |
| Nodes Involvement | 35 % (49) | 23 % (10) | 31 % (11) | 45 % (28) | 0.06 |
| FIGO Stage | I: 56 % (79) II: 9 % (12) III: 29 % (40) IV: 6 % (9) |
I: 67 % (29) II: 9 % (4) III: 16 % (7) IV: 7 % (3) |
I: 57 % (20) II:11 % (4) III: 31 % (11) IV: 0 % (0) |
I: 48 % (30) II: 6 % (4) III: 35 % (22) IV: 10 % (6) |
0.14 |
| Palliated | 13 % (18) | 5 % (2) | 3 % (1) | 25 % (15) | 0.01 |
| Surgery Performed | 89 % (131) | 91 % (41) | 100 % (36) | 81 % (54) | 0.01 |
| Radiotherapy | 43 % (63) | 27 % (12) | 39 % (14) | 55 % (37) | 0.01 |
| Chemotherapy | 13 % (19) | 7 % (3) | 3 % (1) | 23 % (15) | 0.01 |